Literature DB >> 3091067

Kinetics of interaction of C1 inhibitor with complement C1s.

M Lennick, S A Brew, K C Ingham.   

Abstract

The kinetics of inhibition of the complement serine protease, C1s, by its only known inhibitor, C1 inhibitor, have been measured by a variety of methods. One method continuously monitors the loss of esterolytic activity with a synthetic substrate coupled to a chromogen while another monitors the formation of a stable (covalent) complex by high-pressure size-exclusion chromatography under dissociating conditions. Additional methods employ fluorescence probes to follow the formation of bimolecular complexes but are not expected to distinguish between covalent product and noncovalent (reversible) intermediates. There was good agreement between rate constants obtained by the various methods over a broad range of inhibitor concentrations, suggesting that noncovalent intermediates do not accumulate to a significant extent. The reaction appears to be pure second order with a bimolecular rate constant of 6.0 X 10(4) M-1 s-1 at 30 degrees C, independent of Ca2+, and an activation energy of 11.0 kcal/mol. The rate increases up to 35-fold in the presence of heparin which was shown to bind to all three components (enzyme, inhibitor, and complex) with similar affinity (Kd = 2.0-3.3 microM). The fluorescent probe 1,1'-bis(anilino)-4-,4'-bi(naphthalene)-8,8'-disulfonate [bis(ANS)] bound to the complex with Kd = 0.26 microM under conditions where the individual components had little affinity for the dye, consistent with the generation of one or more hydrophobic binding sites on the protein surface during complex formation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091067     DOI: 10.1021/bi00361a023

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.

Authors:  L Bergamaschini; S Canziani; B Bottasso; M Cugno; P Braidotti; A Agostoni
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

2.  alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.

Authors:  Thomas Sulikowski; Bryan A Bauer; Philip A Patston
Journal:  Protein Sci       Date:  2002-09       Impact factor: 6.725

3.  Interaction of heparin with fibronectin and isolated fibronectin domains.

Authors:  K C Ingham; S A Brew; D H Atha
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

4.  C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities.

Authors:  C H Chen; C F Lam; R J Boackle
Journal:  Immunology       Date:  1998-12       Impact factor: 7.397

5.  Recombinant C1 inhibitor P5/P3 variants display resistance to catalytic inactivation by stimulated neutrophils.

Authors:  E Eldering; C C Huijbregts; J H Nuijens; A J Verhoeven; C E Hack
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

6.  Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor.

Authors:  Lakshmi C Wijeyewickrema; Emilie Lameignere; Lilian Hor; Renee C Duncan; Toshikazu Shiba; Richard J Travers; Piyushkumar R Kapopara; Victor Lei; Stephanie A Smith; Hugh Kim; James H Morrissey; Robert N Pike; Edward M Conway
Journal:  Blood       Date:  2016-06-23       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.